Shed vs Hers: Name-brand vs Compounded GLP-1 with Coaching
The Shed vs Hers choice comes down to whether you want both name-brand and compounded GLP-1 with integrated coaching (Shed) or an FDA-approved, name-brand Wegovy® program with a personalized care team (Hers). Early verdict: choose Shed if you want both compounded and brand options plus continuous coaching; choose Hers if you prioritize FDA-approved Wegovy® and a membership-based care team.
Start Shed 2-minute assessment
Shed vs Hers: core difference in medication offerings
Shed lists both FDA-approved name-brand GLP-1s and compounded alternatives on one platform, offering compounded semaglutide and tirzepatide injections and name-brand options. Hers emphasizes FDA-approved Wegovy® (brand-name semaglutide) and states it does not offer compounded medications.
What that means
Shed: the platform explicitly offers compounded medications and notes that compounded medications are not FDA-approved and are prepared by a licensed pharmacy based on a provider’s prescription. Hers: promotes FDA-approved Wegovy® and states name-brand medication with no compounded/generic alternative offered.
Coaching and care model comparison
Shed integrates continuous coaching into treatment, describing coaching as bundled and ongoing rather than a one-time script. Hers provides a personalized care team with ongoing dose check-ins and requires membership for access to medication and care.
Practical effects
Both providers include clinician review before prescriptions are issued, but Shed highlights integrated coaching throughout titration and plateaus. Hers highlights a personalized care team and ongoing dose check-ins tied to its membership model.
Pricing, membership, and starting costs
Both pages supply starting-price cues. Shed lists compounded semaglutide injections starting at $199/month and compounded tirzepatide starting at $299/month and advertises 10% off your first month. Hers lists Wegovy® pill from $149/month and injectable from $199/month but notes an active Hers Weight Loss Membership is required and membership and medication are billed separately.
Key qualifiers
Shed: “Starting at $199/month” for compounded semaglutide and “Starting at $299/month” for compounded tirzepatide; offers 10% off your first month. Hers: “From $149/mo” for some semaglutide options and notes that an active membership is required (initial $39 first month, then auto-renews at $149/month thereafter) and that total cost includes membership plus medication.
Regulatory notes and clinical claims
Both providers include regulatory qualifiers. Shed repeatedly notes that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality, and that treatment is only available when a licensed clinician determines it is medically appropriate. Hers emphasizes FDA-approved Wegovy® and also notes that Ozempic® and other drugs have specific FDA indications and availability limitations, and that treatment is available only when a licensed clinician determines it is medically appropriate.
Side-by-side at-a-glance comparison
| Criteria | Shed | Hers |
|---|---|---|
| Medication options | Offers both name-brand and compounded GLP-1 | Offers FDA-approved Wegovy®; no compounded meds |
| Coaching / care | Continuous coaching integrated into treatment | Personalized care team with ongoing dose check-ins |
| Starting price | Compounded semaglutide starting at $199/month; compounded tirzepatide starting at $299/month; 10% off first month | From $149/mo for some semaglutide options; injectable from $199/mo; membership billed separately |
| Membership required | Not stated as required; coaching bundled into cost | Active membership required; membership fee applies |
| Regulatory note | Compounded meds are not FDA-approved; clinician review required | Promotes FDA-approved Wegovy®; clinician review and state availability limits noted |
How approval and access differ
Shed advertises a fast 2-minute approval assessment to check eligibility, after which a clinician reviews the case and prescriptions are issued if appropriate. Hers does not supply a specific assessment time in the captured evidence but notes prescriptions require clinician eligibility and that some products are not available in all states.
Take Shed 2-minute eligibility check
Shed vs Hers: final guidance
In summary, Shed vs Hers is a choice between a platform that combines both compounded and name-brand GLP-1 options with integrated coaching and a fast 2-minute assessment (Shed) and a platform focused on FDA-approved Wegovy® with a membership-based personalized care team (Hers).
Choose Shed if you want both compounded and name-brand GLP-1 options, integrated continuous coaching, and a 2-minute approval assessment. Choose Hers if you prioritize FDA-approved Wegovy®, a personalized care team with ongoing dose check-ins, and are willing to enroll in a membership for access.